{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:04:17Z","timestamp":1791201857570,"version":"4.2.0"},"reference-count":92,"publisher":"Wiley","issue":"15","license":[{"start":{"date-parts":[[2015,4,17]],"date-time":"2015-04-17T00:00:00Z","timestamp":1429228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:p>\n                    Significant advances have been made in the last decade toward a better understanding of the disease pathogenesis and the development of novel therapies that target specific subsets of adult acute lymphoblastic leukemia (ALL). Risk\u2010adapted strategies are transforming the disease treatment and prognosis. With current treatment regimens, long\u2010term survival is achieved by approximately 50% of patients with B\u2010cell ALL, 50% to 60% of patients with Philadelphia chromosome\u2013positive ALL, and approximately 80% of patients with Burkitt's leukemia. Genomic profiling in ALL has identified new prognostic markers, new therapeutic targets, and novel ALL subtypes. These may be amenable to future targeted therapies that can further improve outcomes. The early recognition of early precursor T\u2010cell ALL, a distinct pathobiological entity with a poor prognosis, is essential for the development of an effective clinical management strategy. The role of monoclonal antibodies and cytotoxic T\u2010cell therapies continues to be defined. Many of the approaches are currently being evaluated for ALL salvage. Their incorporation into frontline adult ALL therapy, in concomitant or sequential strategies, may increase the cure rates to levels achieved in pediatric ALL and may reduce the need for prolonged intensive and maintenance chemotherapy.\n                    <jats:bold>\n                      <jats:italic>Cancer<\/jats:italic>\n                      2015;121:2517\u20132528\n                    <\/jats:bold>\n                    . \u00a9\n                    <jats:italic>2015 American Cancer Society<\/jats:italic>\n                    .\n                  <\/jats:p>","DOI":"10.1002\/cncr.29383","type":"journal-article","created":{"date-parts":[[2015,4,17]],"date-time":"2015-04-17T18:09:46Z","timestamp":1429294186000},"page":"2517-2528","source":"Crossref","is-referenced-by-count":245,"title":["New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia"],"prefix":"10.1002","volume":"121","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,17]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Cancer Facts & Figures 2014","author":"American Cancer Society","year":"2014"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20138"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62187-4"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900386"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-378943"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20668"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09095.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563627"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21776"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9456"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529008"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-261586"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.312"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808253"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70339-5"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403088"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245944"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.469"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-208397"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.06.005"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-235408"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0911726107"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.4105"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2532"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22163"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12736"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308392"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2011.08.001"},{"key":"e_1_2_9_30_1","volume-title":"Arzerra (Ofatumumab) [package insert]","year":"2011"},{"key":"e_1_2_9_31_1","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1200\/jco.2014.32.15_suppl.7065","article-title":"Phase II study of the hyper\u2010CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD\u201020 positive acute lymphoblastic leukemia [abstract]","volume":"32","author":"Jabbour E","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0704"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9456"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.08.021"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1287"},{"key":"e_1_2_9_36_1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1182\/blood.V116.21.173.173","article-title":"Long\u2010term outcome of 335 patients receiving different schedules of imatinib and chemotherapy as front\u2010line treatment for Philadelphia\u2010positive acute lymphoblastic leukemia (Ph+ ALL) [abstract]","volume":"116","author":"Pfeifer H","year":"2010","journal-title":"Blood"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4386"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1343"},{"issue":"1","key":"e_1_2_9_41_1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood.V120.21.138.138","article-title":"Is less chemotherapy detrimental in adults with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia treated with high\u2010dose imatinib? Results of the prospective randomized GRAAPH\u20102005 study [abstract]","volume":"120","author":"Chalandon Y","year":"2012","journal-title":"Blood"},{"issue":"1","key":"e_1_2_9_42_1","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.V120.21.666.666","article-title":"Dasatinib and low intensity chemotherapy for first\u2010line treatment in patients with de novo Philadelphia positive ALL aged 55 and over: final results of the EWALL\u2010Ph\u201001 study [abstract]","volume":"120","author":"Rousselot P","year":"2012","journal-title":"Blood"},{"key":"e_1_2_9_43_1","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.V124.21.798.798","article-title":"Nilotinib (Tasigna) and chemotherapy for first\u2010line treatment in elderly patients with de novo Philadelphia chromosome\/BCR\u2010ABL1 positive acute lymphoblastic leukemia (ALL): a trial of the European Working Group for Adult ALL (EWALL\u2010PH\u201002) [abstract]","volume":"124","author":"Ottman OG","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_44_1","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood.V124.21.797.797","article-title":"First results of the multicenter total therapy GIMEMA LAL 1509 protocol for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) patients [abstract]","volume":"124","author":"Chiaretti S","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.09.028"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205127"},{"key":"e_1_2_9_47_1","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.1200\/jco.2014.32.15_suppl.7064","article-title":"Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients with Philadelphia chromosome positive acute lymphoblastic leukemia [abstract]","volume":"32","author":"O'Brien S","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-466482"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2009.07.008"},{"key":"e_1_2_9_50_1","volume-title":"Arranon (Nelarabine) [package insert]","year":"2011"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70314-0"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-465138"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10725"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-130237"},{"key":"e_1_2_9_55_1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.V124.21.796.796","article-title":"Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of U.S. intergroup trial C10403 [abstract]","volume":"124","author":"Stock W","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6916"},{"key":"e_1_2_9_57_1","first-page":"3900","article-title":"Peg\u2010asparaginase during induction in adult ALL (UKALL14) [abstract]","volume":"122","author":"Patel B","year":"2013","journal-title":"Blood"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28930"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23819"},{"key":"e_1_2_9_60_1","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1182\/blood.V120.21.1493.1493","article-title":"Moderate intensive chemotherapy including CNS\u2010prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph\u2010negative acute lymphoblastic leukemia (ALL): results of a prospective trial from the German Multicenter Study Group for Adult ALL (GMALL) [abstract]","volume":"120","author":"Gokbuget N","year":"2012","journal-title":"Blood"},{"key":"e_1_2_9_61_1","first-page":"428","article-title":"Inotuzumab ozogamicin (IO) in combination with low\u2010intensity chemotherapy as front\u2010line therapy for elderly patients with acute lymphoblastic leukemia [abstract]","volume":"124","author":"Jabbour E","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116582"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.7"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-185132"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2708"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-037093"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-132837"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.17"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-248146"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377713"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2425"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.07.013"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7270"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-441030"},{"key":"e_1_2_9_75_1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood.V124.21.379.379","article-title":"BLAST: a confirmatory, single\u2010arm, phase 2 study of blinatumomab, a bispecific T\u2010cell engager (BiTE) antibody construct, in patients with minimal residual disease B\u2010precursor acute lymphoblastic leukemia (ALL) [abstract]","volume":"124","author":"Goekbuget N","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404824"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.679359"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.1900"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70386-2"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.12.003"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28136"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23901"},{"key":"e_1_2_9_87_1","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1182\/blood.V124.21.2255.2255","article-title":"A phase II study of weekly inotuzumab ozogamicin in adult patients with Cd22\u2010positive acute lymphoblastic leukemia in second or later salvage [abstract]","volume":"124","author":"Advani AS","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"e_1_2_9_93_1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V124.21.384.384","article-title":"Therapy of B cell malignancies with CD19\u2010specific chimeric antigen receptor\u2013modified T cells of defined subset composition [abstract]","volume":"124","author":"Turtle CJ","year":"2014","journal-title":"Blood"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.29383","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.29383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:54:34Z","timestamp":1760298874000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.29383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,17]]},"references-count":92,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1002\/cncr.29383"],"URL":"https:\/\/doi.org\/10.1002\/cncr.29383","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,17]]}}}